Cargando…
Dynamic RMST curves for survival analysis in clinical trials
BACKGROUND: The data from immuno-oncology (IO) therapy trials often show delayed effects, cure rate, crossing hazards, or some mixture of these phenomena. Thus, the proportional hazards (PH) assumption is often violated such that the commonly used log-rank test can be very underpowered. In these tri...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534804/ https://www.ncbi.nlm.nih.gov/pubmed/32854619 http://dx.doi.org/10.1186/s12874-020-01098-5 |